4.7 Article

2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer

Journal

ANNALS OF ONCOLOGY
Volume 26, Issue 8, Pages 1573-1588

Publisher

OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv187

Keywords

non-small-cell lung cancer; locally advanced; stage III; recommendations; ESMO

Categories

Funding

  1. Pfizer
  2. Roche
  3. Boehringer Ingelheim
  4. AstraZeneca
  5. Eli-Lilly Chair in Respiratory Oncology at the Leuven University
  6. AstraZeneca Chair in Personalised Lung Cancer Care at the Leuven University
  7. Eli Lilly
  8. Genentech
  9. Lilly
  10. Endocyte
  11. Novartis
  12. Varian Medical Systems
  13. Covidien
  14. ScreenCell
  15. PointHope
  16. Merck Serono
  17. Cancer Research UK [20465] Funding Source: researchfish

Ask authors/readers for more resources

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on locally advanced disease.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available